Continuing Education: Reviewing Interleukin 17– and Interleukin 23–targeting Therapies and Best Practices in Psoriatic Disease Management Featuring Clinical Practice Video Vignettes
These diseases are chronic, inflammatory, and autoimmune in nature, affecting the skin and often the joints.
Michael Crowe, PharmD, MBA, CSP, FMPA, Registered Manager of General Operations at Community, A Walgreens Pharmacy, in Flint, Michigan; Adjunct Assistant Professor of Clinical Pharmacy at Ferris State University College of Pharmacy in Big Rapids, Michigan
At the conclusion of this activity, the participant will be able to:
- Investigate the pathophysiology of psoriatic disease with a focus on the interleukin 17 and interleukin 23 pathways
- Explore the mechanism of action, safety, efficacy, and role in therapy for current and emerging interleukin 17 and interleukin 23 antagonist biologics for the treatment of psoriasis and/or psoriatic arthritis
- Determine best practices for specialty pharmacists in the management of psoriatic disease
Target Audience: Specialty pharmacists, specialty pharmacy directors/managers, health-system pharmacists, formulary decision makers, and other pharmacists involved in the care of patients with psoriatic disease
Activity Type: Application
Release Date: March 16, 2020
Expiration Date: June 16, 2021
Estimated Time to Complete Activity: 2 hours
Fee: This lesson is offered for free at www.pharmacytimes.org.